Stockscreener 앱 받기
16.30
2.32%
0.37
시간 외 거래:
16.30
전일 마감가:
$15.93
열려 있는:
$16.04
하루 거래량:
794.97K
Relative Volume:
0.50
시가총액:
$1.42B
수익:
-
순이익/손실:
$-162.45M
주가수익비율:
-8.7418
EPS:
-1.8646
순현금흐름:
$-146.72M
1주 성능:
+6.89%
1개월 성능:
+10.81%
6개월 성능:
+51.77%
1년 성능:
+301.48%
1일 변동 폭
$15.83
$16.51
1주일 범위
$15.55
$16.99
52주 변동 폭
$3.89
$36.26
올레마 Stock (OLMA) Company Profile
명칭
Olema Pharmaceuticals Inc
전화
(415) 651-3316
주소
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
16.30 | 1.40B | 0 | -162.45M | -146.72M | -1.8646 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
올레마 Stock (OLMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 개시 | Wolfe Research | Peer Perform |
| 2026-03-19 | 재개 | Jefferies | Buy |
| 2026-02-11 | 개시 | Stifel | Buy |
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-10-08 | 개시 | Guggenheim | Buy |
| 2025-08-12 | 재확인 | Citigroup | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2024-01-30 | 개시 | Citigroup | Buy |
| 2023-07-21 | 개시 | Oppenheimer | Outperform |
| 2023-05-05 | 개시 | CapitalOne | Overweight |
| 2023-02-22 | 개시 | Credit Suisse | Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-06-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | 개시 | H.C. Wainwright | Neutral |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2020-12-14 | 개시 | Canaccord Genuity | Buy |
| 2020-12-14 | 개시 | Cowen | Outperform |
| 2020-12-14 | 개시 | JP Morgan | Overweight |
| 2020-12-14 | 개시 | Jefferies | Buy |
모두보기
올레마 주식(OLMA)의 최신 뉴스
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest Update - MarketBeat
Rate Cut: Is Olema Pharmaceuticals Inc forming bullish engulfing patterns2026 Setups & Stock Portfolio Risk Management - baoquankhu1.vn
Olema Pharmaceuticals (NASDAQ:OLMA) Raised to "Sell" at Wall Street Zen - MarketBeat
Olema Pharmaceuticals posts new leadership role to advance clinical study compliance - Traders Union
Aurigene Oncology and Olema Pharmaceuticals patent KAT6A degradation inducers - BioWorld News
Olema Pharmaceuticals (NASDAQ:OLMA) Trading 7.7% HigherHere's What Happened - MarketBeat
Sentiment Review: Is Olema Pharmaceuticals Inc stock trending bullish2026 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Market Review: How does Olema Pharmaceuticals Inc perform in inflationary periods2026 Institutional Moves & Daily Growth Stock Tips - baoquankhu1.vn
SG Americas Securities LLC Purchases Shares of 69,382 Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
OLMA SEC FilingsOlema Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
OLMA Technical Analysis & Stock Price Forecast - Intellectia AI
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 8.4%Still a Buy? - MarketBeat
Targets Report: How does Olema Pharmaceuticals Inc perform in inflationary periodsMarket Sentiment Review & Technical Buy Zone Confirmation - baoquankhu1.vn
A Look At Olema Pharmaceuticals (OLMA) Valuation After Earnings And New Shelf Registration Filing - Sahm
Hennion & Walsh Asset Management Inc. Increases Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals Inc at Citi Oncology Leadership Summit (Virtual) Transcript - GuruFocus
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Wolfe Research initiates coverage of Olema Pharmaceuticals (OLMA) with peer perform recommendation - MSN
Wolfe Research Initiates Coverage on Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals seeks senior director to lead accounting operations and financial reporting - Traders Union
Buybacks Report: Will Olema Pharmaceuticals Inc outperform its industry peers2026 Key Highlights & Expert Approved Trade Ideas - baoquankhu1.vn
Aug PostEarnings: What are analysts price targets for Olema Pharmaceuticals IncWeekly Stock Report & Reliable Intraday Trade Alerts - baoquankhu1.vn
Oppenheimer maintains Olema Pharmaceuticals (OLMA) outperform recommendation - MSN
Jim Cramer on Olema Pharmaceuticals: "Too risky for me" - MSN
Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me” - Insider Monkey
Olema Shelf Registration Raises Questions On Dilution And Funding Flexibility - Yahoo Finance
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? - AOL.com
Invus entities disclose 4.5% stake in Olema (OLMA) on Schedule 13G - Stock Titan
Jefferies Adjusts Price Target for Olema Pharmaceuticals (OLMA) - GuruFocus
Olema Pharmaceuticals (OLMA) loses 33.4% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Jefferies Adjusts Price Target for Olema Pharmaceuticals (OLMA) | OLMA Stock News - GuruFocus
Olema Pharmaceuticals (OLMA) Is Down 6.7% After Posting Wider Losses And Filing New Stock Shelf - simplywall.st
Jefferies Financial Group Begins Coverage on Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Jefferies initiates Olema Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada
LifeSci Capital reiterates a buy on Olema Pharmaceuticals (OLMA) - MSN
JP Morgan Raises Price Target for Olema Pharmaceuticals (OLMA) | - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Olema Pharmaceuticals (OLMA) Drops 33.4% Over Past Month, Reasons Suggest a Potential Turnaround Ahead - Bitget
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Olema Pharmaceuticals (OLMA) Receives Updated Price Target by Go - GuruFocus
The Goldman Sachs Group Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
HC Wainwright Issues Optimistic Outlook for OLMA Earnings - MarketBeat
OLMA: Guggenheim Lowers Price Target While Maintaining Buy Ratin - GuruFocus
Olema Pharmaceuticals (OLMA) Receives Increased Price Target fro - GuruFocus
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting - Bitget
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Citigroup Forecasts Strong Price Appreciation for Olema Pharmaceuticals (NASDAQ:OLMA) Stock - MarketBeat
올레마 (OLMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.81%
자본화:
|
볼륨(24시간):